Here are five takeaways:
1. The company earned $11.5 million in this financing round.
2. The round was led by investors Research Corporation Technologies and California Technology Ventures.
3. The funds will be used to expand sales and distribution and further support the continued rollout of the company’s QB1 system.
4. The CyMedica QB1 system is intended for the treatment of quadriceps muscle atrophy.
5. In April, the system received 510(k) clearance and it was launched at the Arthroscopy Association of North American Arthroscopic Society for Sports Medicine annual meeting in Los Angeles.
More articles on devices:
SpineGuard completes $3.1M fresh equity round — 5 things to know
ApiFix used in 50th scoliosis correction — 5 key notes
InVivo Therapeutics names Dr. James Guest to scientific advisory board — 5 key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
